# US 2003/0079244 A1 · Agent for treatment of exocrine gland disorders and transgenic mouse useful for screening the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0079244 A1
- Document ID: US20030079244A1
- Status: Published application
- Kind: A1
- Application number: 10/301,921
- Filed: 2002-11-22
- Published: 2003-04-24
- Earliest claimed: 1997-01-10
- Assignees: R-Tech Ueno, Ltd.
- Inventors: Kazuo Tsubota; Ichiro Saito
- Web page: https://patentgrep.com/patent/US20030079244A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 14/5428: {IL-10}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

An agent for treating exocrine gland disorders by inhibiting the production and/or an activity of interleukin-10; and a transgenic mouse useful for screening the same wherein interleukin-10 is specifically expressed in its exocrine glands.

## Claims

### Claim 1

Agent for treatment of exocrine gland disorders, comprising a substance which inhibits the production and/or an activity of interleukin-10 as an active ingredient.

### Claim 2 (depends on 1)

The agent of claim 1, wherein the substance which inhibits the production and/or an activity of interleukin-10 is anti-Fas ligand antibody.

### Claim 3

A method for screening an agent for treatment of exocrine gland disorders, comprising the step of detecting cytotoxic ability of Fas-ligand expressed by interleukin-10.

### Claim 4

A method for screening an agent for treatment of exocrine gland disorders, comprising the steps of:
adding effector cells, which are obtainable by treating said cells with interleukin-10, to aliquots of exocrine gland target cells;
adding to the resulting cell mixtures either interleukin-10 alone or a mixture of interleukin-10 and a substrate to be screened;
incubating the cell mixtures; and
calculating the cytotoxic ratio from the amount of damaged target cells occurs in the respective cell mixtures.

### Claim 5

A plasmid comprising the following restriction map:
3
which is obtainable by ligating 640 bp of splicing region of rabbit beta globulin to 828 bp of human amylase promoter and 594 bp of IL-10 cDNA to the 3′-terminal of the splicing region.

### Claim 6 (depends on 5)

A plasmid vector obtainable by inserting the plasmid of claim 5 into vector pBR322.

### Claim 7

A method for preparing a plasmid vector comprising the steps of:
ligating rabbit beta globulin splicing region to BamH1 digested fragment of human exocrine gland promoter,
ligating EcoR1 digested fragment of mouse interleukin-10 cDNA to the 3′ end of the splicing region; and
inserting the resulting plasmid into a selective marker.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the respective ligating steps is performed with T4 ligase.

### Claim 9 (depends on 6)

A mouse fertilized oocyte into which the plasmid vector of claim 6 is inserted.

### Claim 10 (depends on 5)

A transgenic mouse which carries the plasmid gene of claim 5.
